Targeting C<sub>18:0</sub>, but not C<sub>16:0</sub>, ceramides in skeletal muscle to alleviate glucose intolerance — ASN Events
  1. Schedule
  2. ADS Basic Orals: Lipids, Cytokines and Glucose Tolerance
  3. Targeting C18:0, but not C16:0, ceramides in skeletal muscle to alleviate glucose intolerance

Targeting C18:0, but not C16:0, ceramides in skeletal muscle to alleviate glucose intolerance (#190)

Sarah Turpin 1 2 , Philipp Hammerschmidt 1 2 , Katharina Timper 1 2 , Susanne Brodessor 2 , Matthias Blüher 3 , Martin Krönke 2 , Jens Brüning 1 2
  1. Max Planck Insititute for Metabolism Research, Cologne, Germany
  2. CECAD, Cologne, Germany
  3. Department of Medicine, University of Leipzig, Leipzig, Germany
Publish consent withheld
  1. Turpin et al., Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metabolism, 2014; 20(4).
  2. Zhao et al., A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation. PLoS Genetics, 2011; 7(5).
  3. This work was funded by the Deutsche Zentrum für Diabetesforschung (DZD), Germany.